A share price of Apogee Therapeutics Inc [APGE] is currently trading at $77.3, down -0.90%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The APGE shares have gain 3.37% over the last week, with a monthly amount glided 16.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apogee Therapeutics Inc [NASDAQ: APGE] stock has seen the most recent analyst activity on December 17, 2025, when Stephens initiated its Overweight rating and assigned the stock a price target of $95. Previously, Deutsche Bank started tracking the stock with Buy rating on December 10, 2025, and set its price target to $103. On November 03, 2025, Craig Hallum initiated with a Buy rating and assigned a price target of $109 on the stock. Mizuho started tracking the stock assigning a Outperform rating and suggested a price target of $105 on October 21, 2025. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $60 as its price target on September 25, 2025. BTIG Research reiterated a Buy rating for this stock on July 07, 2025, and upped its price target to $115. In a note dated March 13, 2025, Citigroup initiated an Buy rating and provided a target price of $95 on this stock.
Apogee Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $26.20 and $80.99. Currently, Wall Street analysts expect the stock to reach $91.75 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $77.3 at the most recent close of the market. An investor can expect a potential return of 18.69% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.35 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 76.05 points at the first support level, and at 74.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 79.49, and for the 2nd resistance point, it is at 81.69.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Apogee Therapeutics Inc [NASDAQ:APGE] is 15.86. As well, the Quick Ratio is 15.86, while the Cash Ratio is 3.17.
Transactions by insiders
Recent insider trading involved Henderson Jane, Chief Financial Officer, that happened on Dec 19 ’25 when 1500.0 shares were sold. Officer, JANE HENDERSON completed a deal on Dec 19 ’25 to buy 1500.0 shares. Meanwhile, Chief Executive Officer HENDERSON MICHAEL THOMAS sold 20000.0 shares on Dec 10 ’25.
